雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性分析
|
摘要
目的探讨腹腔镜结直肠癌根治术中雷替曲塞用于腹腔灌注化疗的安全性。方法从我院2017年5月～2018年5月选取58例行腹腔镜结直肠癌根治术的结直肠癌患者,将患者随机分成两组,每组29例。对照组采用常规手术方式,观察组采用术中雷替曲塞腹腔灌注化疗的方式。观察比较两组患者的相关毒性指标和不良反应发生情况。结果观察组患者治疗后白细胞计数(WBC)、红细胞计数(RBC)、血肌酐(Cr)、血小板计数(PLT)、尿素氮(BUN)、天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)指标与对照组无显著差异(P>0.05),观察组不良反应发生率为31.03%,相比对照组不良反应发生率为37.93%,两组数据差异无统计学意义(P>0.05)。结论腹腔镜结直肠癌根治术中雷替曲塞用于腹腔灌注化疗,不会增加患者的毒副作用和不良反应,具有较好的安全性。
Objective To investigate the safety of raltitrexed for intraperitoneal chemotherapy in laparoscopic radical resection of colorectal cancer. Methods From May 2017 to May 2018, 58 patients with colorectal cancer who underwent laparoscopic radical resection of colorectal cancer were selected and randomly divided into two groups, with 29 cases in each group. The control group was given conventional surgical approach. The observation group was treated with intraoperative intraperitoneal chemotherapy with raltitrexed. The relevant toxicity indicators and adverse reactions occurred in the two groups were observed and compared. Results There was no significant difference in white blood cell count(WBC), red blood cell count(RBC), serum creatinine(Cr), platelet count(PLT), urea nitrogen(BUN), aspartate aminotransferase(AST), and alanine aminotransferase(ALT) between the observation group and the control group after treatment(P>0.05). The incidence of adverse reactions in the observation group was 31.03%, and the incidence of adverse reactions in the control group was 37.93%. There was no significant difference between the two groups(P>0.05). Conclusion In the laparoscopic radical resection of colorectal cancer, raltitrexed for intraperitoneal chemotherapy does not increase the side effects and adverse reactions of patients, and has good safety.
Objective To investigate the safety of raltitrexed for intraperitoneal chemotherapy in laparoscopic radical resection of colorectal cancer. Methods From May 2017 to May 2018, 58 patients with colorectal cancer who underwent laparoscopic radical resection of colorectal cancer were selected and randomly divided into two groups, with 29 cases in each group. The control group was given conventional surgical approach. The observation group was treated with intraoperative intraperitoneal chemotherapy with raltitrexed. The relevant toxicity indicators and adverse reactions occurred in the two groups were observed and compared. Results There was no significant difference in white blood cell count(WBC), red blood cell count(RBC), serum creatinine(Cr), platelet count(PLT), urea nitrogen(BUN), aspartate aminotransferase(AST), and alanine aminotransferase(ALT) between the observation group and the control group after treatment(P>0.05). The incidence of adverse reactions in the observation group was 31.03%, and the incidence of adverse reactions in the control group was 37.93%. There was no significant difference between the two groups(P>0.05). Conclusion In the laparoscopic radical resection of colorectal cancer, raltitrexed for intraperitoneal chemotherapy does not increase the side effects and adverse reactions of patients, and has good safety.
引文
[1]徐建军,刘殿明.雷替曲塞以腹腔/静脉给药途径治疗结直肠癌腹水的疗效比较[J].东南国防医药,2015,(1):38-39.
[2]臧金林,周东风.直肠癌Dixon术中应用雷替曲塞的安全性评估[J].中国现代普通外科进展,2016,19(12):960-962.
[3]应浩杰,王乃金,史进,等.雷替曲塞在进展期结直肠癌腹腔灌洗化疗的应用[J].实用医药杂志,2017,(11):1005-1006.
[4]李立军,王玉美.雷替曲塞腹腔灌注治疗结肠癌腹膜转移并发严重骨髓抑制1例[J].山西医科大学学报,2017,48(6):639-640.
[5]顾敏,陈吉祥,瞿建国,等.术中灌注雷替曲塞治疗老年结直肠癌安全性评估[J].结直肠肛门外科,2015,21(S1):12.
[6]张红彬,李蜀华,曹万龙.术中雷替曲塞腹腔灌洗在结直肠癌根治术后预防复发的效果[J].中国临床研究,2018,31(4):89-91.
[7]罗云号,李洋,李超宇,等.T3以上结肠癌腹腔镜根治术后雷替曲塞联合奥沙利铂进行预防性腹腔热灌注化疗的临床研究[J].现代医药卫生,2018,34(11):1648-1651.
[8]张洋,陈志康,郭雄,等.雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究[J].中国临床药理学与治疗学,2018,23(3):313-318.
[9]李恒平,张晓磊.雷替曲塞联合腹腔镜胃癌根治术治疗晚期胃癌的疗效分析[J].中国处方药,2018,(3):70-71.
[10]宁昌,王洋,王志刚.雷替曲塞治疗老年晚期结直肠癌21例临床观察[J].海南医学,2011,22(10):61-63.
[11]杨柳,张玉涛.分析注射用雷替曲塞治疗老年晚期结直肠癌的效果[J].中国实用医药,2014,(26):147-148.
[12]朱群山,王昊,郑广万,等.腹腔镜直、乙状结肠癌根治术中保留雷替曲塞腹腔化疗的耐受性及安全性[J].皖南医学院学报,2018,(1):32-35.
[13]张琳,陈瑞云,王志伟.经腹腔镜结直肠癌根治术后早期腹腔热灌注化疗的临床观察[J].中国临床研究,2016,29(10):1372-1374.
[14]项慧,马驱.结直肠癌术后应用雷替曲塞联合奥沙利铂辅助化疗的疗效观察[J].结直肠肛门外科,2017,(1):46-49.
[15]薛苏阳,李佳睿,张文雷,等.应用雷替曲塞行介入治疗结直肠癌肝转移的疗效[J].中国老年学杂志,2014,34(10):2887-2888.
[2]臧金林,周东风.直肠癌Dixon术中应用雷替曲塞的安全性评估[J].中国现代普通外科进展,2016,19(12):960-962.
[3]应浩杰,王乃金,史进,等.雷替曲塞在进展期结直肠癌腹腔灌洗化疗的应用[J].实用医药杂志,2017,(11):1005-1006.
[4]李立军,王玉美.雷替曲塞腹腔灌注治疗结肠癌腹膜转移并发严重骨髓抑制1例[J].山西医科大学学报,2017,48(6):639-640.
[5]顾敏,陈吉祥,瞿建国,等.术中灌注雷替曲塞治疗老年结直肠癌安全性评估[J].结直肠肛门外科,2015,21(S1):12.
[6]张红彬,李蜀华,曹万龙.术中雷替曲塞腹腔灌洗在结直肠癌根治术后预防复发的效果[J].中国临床研究,2018,31(4):89-91.
[7]罗云号,李洋,李超宇,等.T3以上结肠癌腹腔镜根治术后雷替曲塞联合奥沙利铂进行预防性腹腔热灌注化疗的临床研究[J].现代医药卫生,2018,34(11):1648-1651.
[8]张洋,陈志康,郭雄,等.雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究[J].中国临床药理学与治疗学,2018,23(3):313-318.
[9]李恒平,张晓磊.雷替曲塞联合腹腔镜胃癌根治术治疗晚期胃癌的疗效分析[J].中国处方药,2018,(3):70-71.
[10]宁昌,王洋,王志刚.雷替曲塞治疗老年晚期结直肠癌21例临床观察[J].海南医学,2011,22(10):61-63.
[11]杨柳,张玉涛.分析注射用雷替曲塞治疗老年晚期结直肠癌的效果[J].中国实用医药,2014,(26):147-148.
[12]朱群山,王昊,郑广万,等.腹腔镜直、乙状结肠癌根治术中保留雷替曲塞腹腔化疗的耐受性及安全性[J].皖南医学院学报,2018,(1):32-35.
[13]张琳,陈瑞云,王志伟.经腹腔镜结直肠癌根治术后早期腹腔热灌注化疗的临床观察[J].中国临床研究,2016,29(10):1372-1374.
[14]项慧,马驱.结直肠癌术后应用雷替曲塞联合奥沙利铂辅助化疗的疗效观察[J].结直肠肛门外科,2017,(1):46-49.
[15]薛苏阳,李佳睿,张文雷,等.应用雷替曲塞行介入治疗结直肠癌肝转移的疗效[J].中国老年学杂志,2014,34(10):2887-2888.